Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

CJC-1295 and GHRP-6 Blend - Potential Actions on GH Synthesis

CJC-1295 and GHRP-6 Blend – Potential Actions on Growth Hormone Synthesis & Anabolic Signaling Aug 8, 2025 CJC-1295 appears to interact with the main receptors on the anterior pituitary gland cells, which normally respond to GHRH (growth hormone-releasing horm

By Recovery & Performance Peptides Editorial Team

CJC-1295 and GHRP-6 Blend – Potential Actions on Growth Hormone Synthesis & Anabolic Signaling

Aug 8, 2025

CJC-1295 appears to interact with the main receptors on the anterior pituitary gland cells, which normally respond to GHRH (growth hormone-releasing hormone). On the other hand, GHRP-6 may interact with an alternative set of receptors that normally respond to a particular hunger hormone called ghrelin. Researchers are actively investigating the potential complementary or synergistic actions of the two peptides, as they appear to interact via different mechanisms and thus may exert an even greater stimulus on hGH-producing pituitary gland cells.

Research

Peptide Structures of CJC-1295 and GHRP-6

CJC-1295 and GHRP-6 have distinct structures. Interaction with catalyzing forces found in research models has the potential to result in different receptor affinities. CJC-1295 is a synthetic peptide based on the first 29 amino acids of the endogenous growth hormone-releasing hormone (GHRH). However, this 29-amino acid structure was modified to replace four specific amino acids — at positions 2, 8, 15, and 27 — that potentially make it less vulnerable to rapid clipping and deactivation by enzymes such as dipeptidyl peptidase-4.

By slowing this enzymatic breakdown, the peptide might remain intact long enough to continue signaling. In addition to these swaps, CJC-1295 is thought to include a drug-affinity complex (DAC) tag at its carboxyl end. Chemically described as an N-Ε-3-Maleimidopropionamide derivative, this tag may bind to abundant plasma proteins, thereby mitigating its rapid clearance by detoxification mechanisms. Early pharmacokinetic studies, such as those by Jetté et al., comment that the peptide “was found to be present in plasma beyond 72 h,” which is considerably longer than the 10-minute half-life of the unmodified GHRH 1-29 sequence.(1) That said, GHRP-6 peptide was pioneered by researchers such as Bowers et al., and its structure was not based on an endogenously occurring hormone, but rather an analog of a neuromediator called met-enkephalin.(2)

GHRP-6 is a synthetic hexapeptide.

Despite this structural basis, the GHRP-6 peptide does not have any related opioid receptor signaling. Instead, GHRP-6 appears to interact with the receptors of another hormone called ghrelin. This is a hunger hormone that may interact with pituitary gland cells via a different set of receptors, called ghrelin receptors or Growth Hormone Secretagogue Receptors (GHS-receptors).

CJC-1295 and GHRP-6 Receptor Affinities

Research by Culhane et al. suggests that peptides like CJC-1295 may bind to the GHRH receptor on anterior pituitary gland cells, triggering a chain reaction.(3) The receptor may activate intracellular G proteins, which then boost levels of a small molecule called cAMP. Rising cAMP is believed to potentially contribute to the “turning on” of protein kinase A, an enzyme that helps switch on the cell’s machinery for making and releasing hGH. More specifically, this may promote intracellular events such as calcium influx and transcriptional changes, which are needed to drive hGH synthesis and release.

In comparison to endogenous GHRH, the GHRH receptor might stay engaged and keep the cAMP pathway active over an extended period. In turn, pituitary cells may be nudged into producing more hGH or keeping hGH production going for longer than usual. In contrast, GHRP-6 appears to target pituitary gland cells by binding to their GHS-receptors, also called GHS-R1a. Similar to their activation by ghrelin, research by Yin et al. highlights that peptides like GHRP-6 may activate an enzyme called phospholipase C (PLC) when docking to the receptor.(4) PLC then may cleave a membrane lipid (PIP₂) into two “second messengers”: IP₃ (inositol 1,4,5-trisphosphate) and DAG (diacylglycerol). IP₃ may diffuse into the cell’s interior and open calcium channels on the endoplasmic reticulum, causing stored calcium to flood into the cytoplasm.

Meanwhile, DAG remains in the membrane and helps activate protein kinase C (PKC). The combined surge in intracellular calcium and PKC activity serves as the key signal that drives growth hormone–loaded granules toward the cell surface, where they fuse with the membrane and release hGH. Because this IP₃/DAG-driven pathway is distinct from the cAMP-focused mechanism of GHRH analogues like CJC-1295, researchers are studying whether using both peptides together may yield a stronger or more sustained boost in hGH production.

Interestingly, GHRP-6 may also have affinity to receptors unrelated to the pituitary gland cells, such as the CD36 receptors. CD36 is a scavenger receptor found on macrophages and endothelial cells. Research by Demers et al. suggests that the peptide’s contact points may be a stretch of CD36 between amino acids 132 and 177, with a critical interaction at methionine-169.(5) The scientists also suggested that GHRP-6 may displace oxidized low-density lipoprotein (oxLDL) from this same region, suggesting that it docks into the CD36 pocket that normally recognizes modified lipoproteins.

By binding CD36 at or near Met169, GHRP-6 may partially block oxLDL uptake by macrophages and interfere with thrombospondin-1 signaling in the endothelium. In experimental models, this may translate into reduced foam cell formation and altered angiogenic responses—mechanisms that might contribute to the anti-atherosclerotic actions of GHRPs.

Individual and Synergistic Potential of the CJC-1295 and GHRP-6 Blend

Both CJC-1295 and CHRP-6 have been studied separately regarding their potential hGH-stimulating actions on anterior pituitary gland cells. Notably, experimental work by Teichman and colleagues indicates that CJC-1295 may boost “GH concentrations by 2- to 10-fold for 6 d or more”.(6) Moreover, the researchers reported that while the peak was sustained for almost a week, it appeared to occur about two hours after exposure.

Further research by Micle et al. suggests that GHRP-6 may also provoke a substantial rise in hGH levels on its own.(7) The researchers observed that a single exposure may lift peak GH concentrations to around 60 mU/L—approximately a 30- to 50-fold jump over baseline (which typically sits near 1–2 mU/L), and over 3-fold compared to physiological peaks (up to 20 mU/L).

Moreover, Micle et al. investigated the combined potential of GHRP-6 with a GHRH-analog (although not CJC-1295, but the full GHRH sequence), and they suggested that the blend may push peak GH into the neighborhood of 140 mU/L, roughly doubling the GHRP-6–only response and representing a ~70- to 100-fold increase over baseline.(7) These observations suggest that combining a ghrelin-mimetic peptide like GHRP-6 with a GHRH-based compound like CJC-1295 may potentially amplify hGH release more than either agent alone, perhaps by engaging both the GHS-R and GHRH-R pathways to deliver a more sustained or synergistic stimulus to somatotroph cells in research settings.

Cordido et al. also evaluated the synergistic potential of GHRP-6 with GHRH-analogs (again, not CJC-1295, but the full GHRH sequence).(8) When pituitary cells were exposed to GHRP-6 alone, the average GH peak rise was suggested to be about 6 mU/L (15.7 ± 4.4 pg/L), compared with a baseline near zero. In contrast, exposure to a GHRH analogue alone appeared to yield a smaller GH peak of roughly 2.6 mU/L (6.8 ± 1.1 pg/L), implying that GHRP-6 may induce about a 2.3-fold larger acute response than GHRH in this setting.

Looking at overall secretion, the GH area under the curve (AUC) with GHRP-6 alone was suggested to be around 260 mU·min/L (674 ± 187 pg·min/L), versus 159 mU·min/L (412 ± 71 pg·min/L) for GHRH, again suggesting a roughly 1.6-fold greater cumulative release with GHRP-6. Most notably, when pituitary cells are simultaneously challenged with both GHRP-6- and GHRH-type peptides, mean GH peaks appeared to climb to 16.3 mU/L (42.2 ± 10.9 pg/L)—approximately 2.7 times the GHRP-6–only peak and 6.2 times the GHRH-only peak.

The combined AUC also jumps to about 729 mU·min/L (1,894 ± 784 pg·min/L), nearly 2.8-fold higher than GHRP-6 alone and 4.6-fold higher than GHRH alone.(8) It’s important to note, however, that the experiments used related GHRH analogues rather than CJC-1295, so the precise degree of synergy between the latter and GHRP-6 remains to be established.

Anabolic Potential of the CJC-1295 and GHRP-6 Blend

The apparent increase in hGH levels by CJC-1295 and GHRP-6 may also upregulate anabolic signaling. Specifically, growth hormone may engage receptors on hepatocytes, myocytes, and other target cells. This may play a role in triggering intracellular cascades such as the Janus kinase–signal transducer and activator of transcription (JAK-STAT) pathway.

Research by Himpe et al. suggests that upon receptor binding, associated JAK kinases might phosphorylate STAT proteins, which may then translocate into the nucleus and bind to specific response elements on DNA.(9) This sequence of events may drive the transcription of genes responsible for insulin-like growth factor-1 (IGF-1) production, the principal anabolic effector of GH.

As suggested by the experiments mentioned above, both CJC-1295 and GHRP-6 are expected to boost GH release and, consequently, IGF-1 synthesis. Indeed, Teichman et al. suggest that CJC-1295 may increase average IGF-1 concentrations by approximately 1.5- to 3-fold throughout 9 to 11 days, and that continued exposure to the peptide may help maintain these elevated levels for up to 28 days.(6) Unfortunately, no studies have measured IGF-1 level changes when investigating the potential of GHRP-6 alone or in combination with GHRH-analog only.

Considering the synergistic potential suggested by the experiments of Micic et al. and Cordido et al., a similar synergistic increase in the anabolic signalling by IGF-1 levels may be expected.(7)(8) Future research should aim at investigating this specific synergistic potential between CJC-1295 and GHRP-6 in laboratory settings.

You can find CJC-1295 & GHRP-6 Blend for sale with 99% purity, on our website (available for research use only).

NOTE: These products are intended for laboratory research use only. This peptide is not intended for personal use. Please review and adhere to our Terms and Conditions before ordering.

References:

Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005 Jul;146(7):3052-8. doi: 10.1210/en.2004-1286. Epub 2005 Apr 7. PMID: 15817669.

Bowers CY. History to the discovery of ghrelin. Methods Enzymol. 2012;514:3-32. doi: 10.1016/B978-0-12-381272-8.00001-5. PMID: 22975043.

Culhane KJ, Liu Y, Cai Y, Yan EC. Transmembrane signal transduction by peptide hormones via family B G protein-coupled receptors. Front Pharmacol. 2015 Nov 5;6:264. doi: 10.3389/fphar.2015.00264. PMID: 26594176; PMCID: PMC4633518.

Yin Y, Li Y, Zhang W. The growth hormone secretagogue receptor: its intracellular signaling and regulation. Int J Mol Sci. 2014 Mar 19;15(3):4837-55. doi: 10.3390/ijms15034837. PMID: 24651458; PMCID: PMC3975427.

Demers A, McNicoll N, Febbraio M, Servant M, Marleau S, Silverstein R, Ong H. Identification of the growth hormone-releasing peptide binding site in CD36: a photoaffinity cross-linking study. Biochem J. 2004 Sep 1;382(Pt 2):417-24. doi: 10.1042/BJ20040036. PMID: 15176951; PMCID: PMC1133797.

Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006 Mar;91(3):799-805. doi: 10.1210/jc.2005-1536. Epub 2005 Dec 13. PMID: 16352683.

Micic D, Popovic V, Kendereski A, Macut D, Casanueva FF, Dieguez C. Growth hormone secretion after the administration of GHRP-6 or GHRH combined with GHRP-6 does not decline in late adulthood. Clin Endocrinol (Oxf). 1995 Feb;42(2):191-4. doi: 10.1111/j.1365-2265.1995.tb01861.x. PMID: 7734029.

Cordido F, Peñalva A, Dieguez C, Casanueva FF. Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity. J Clin Endocrinol Metab. 1993 Apr;76(4):819-23. doi: 10.1210/jcem.76.4.8473389. PMID: 8473389.

Himpe E, Kooijman R. Insulin-like growth factor-I receptor signal transduction and the Janus Kinase/Signal Transducer and Activator of Transcription (JAK-STAT) pathway. Biofactors. 2009 Jan-Feb;35(1):76-81. doi: 10.1002/biof.20. PMID: 19319849.

Dr. Marinov

Dr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.

Latest Blog Articles

Thymogen Potential in Immune Cell Regulation

CJC-1295 & Hexarelin Blend Potential for Growth Hormone Signaling Stimulation

Oxytocin Actions On Neuronal Circuits in Different Mammalian Research Models

Kisspeptin 45-54 Peptide Interactions with Hypothalamic and Neuronal Cells

T-31 Peptide Interactions with Cellular Aging, Renewal, and Stress Pathways

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

Dosing Protocols and Administration Timing for CJC-1295

Research-grade CJC-1295 dosing in human trials has ranged from 30mcg/kg to 60mcg/kg administered subcutaneously once weekly. For a 75kg individual, this translates to approximately 2.25mg per injection. The dose-response curve shows diminishing returns above 60mcg/kg. Higher doses produce marginal additional IGF-1 elevation but increase the incidence of transient side effects like injection site reactions and mild water retention. Most published recomposition protocols use the lower end (30–45mcg/kg weekly) to balance efficacy with tolerability. Timing relative to training and feeding windows is frequently debated but lacks strong empirical support. CJC-1295's extended half-life means plasma concentrations remain relatively stable across the week. There is no acute post-injection GH spike that benefits from specific nutrient timing. Some researchers prefer evening administration to align with natural nocturnal GH pulses, but controlled trials show no significant difference in IGF-1 response between morning and evening dosing. Consistency matters more than timing. Reconstitution requires bacteriostatic water at a 1:1 or 2:1 ratio (2mg peptide in 1–2mL water), with the solution refrigerated at 2–8°C and used within 28 days. Lyophilised powder should be stored at −20°C before reconstitution. Temperature excursions above 8°C after mixing cause irreversible protein denaturation. A single overnight mistake renders the peptide inactive, though visual inspection won't reveal degrada…
STORAGE

The Blunt Truth About CJC-1295 Storage

Here's the honest answer: if you left reconstituted CJC-1295 out of the fridge for more than 24 hours, it's ruined. Not 'maybe less effective'. Ruined. The thermal denaturation that occurs at room temperature is irreversible. Refrigerating it afterward doesn't restore potency. The aggregated proteins can't unfold back into their bioactive conformation. This isn't a 'use it and see' situation. Using degraded peptides in research introduces uncontrolled variables that compromise data integrity. The cost of discarding one vial is trivial compared to the cost of running an entire study on unreliable compounds. If the peptide was lyophilized and the excursion was brief, you're fine. If it was reconstituted and sat out overnight, start fresh.
02

Question drills

Open a question for its connected answer.

01What If Long-Term Safety Data Beyond 12 Weeks Doesn't Exist in Animal Models?+

It largely doesn't—most cjc-1295 animal research spans 8–12 weeks, occasionally extending to 16 weeks in primate models. Chronic effects (pituitary adenoma risk, joint degeneration, insulin resistance progression) require 6–12 month timelines to manifest, and no published study has run that duration in a controlled animal cohort. The implication: human use extending beyond 3–4 months operates outside the evidence base established by animal research. That doesn't mean it's unsafe—it means the long-term risk profile is inferred from exogenous GH studies, not directly tested with CJC-1295.

SOURCE / realpeptides.co ↗
02What If Human Dosing Extrapolated from Animal Studies Produces Suboptimal Results?+

Recalculate based on receptor occupancy or plasma exposure targets, not body weight ratios. CJC-1295 human trials used 60 mcg/kg as the effective dose, which is proportionally lower than the 100–300 mcg/kg range used in rodents when adjusted for metabolic rate and receptor density. If direct weight-based extrapolation underperforms, the issue is typically feedback inhibition (humans have stronger somatostatin tone) or receptor saturation (human GHRH receptor density is lower). Empirical dose-finding in humans is required. Animal doses predict starting points, not final protocols.

SOURCE / realpeptides.co ↗
03What If I Experience Joint Pain or Swelling Within the First Month?+

Reduce dose by 50% immediately and retest IGF-1 within one week. Joint swelling. Particularly in fingers, wrists, and ankles. Indicates excessive fluid retention driven by supraphysiological IGF-1 elevation. This occurs when IGF-1 exceeds 320–350 ng/mL and activates aldosterone-mediated sodium retention. The swelling isn't permanent, but continuing at the same dose risks carpal tunnel syndrome and reduced insulin sensitivity. If symptoms persist after dose reduction, discontinue for two weeks to allow IGF-1 to return to baseline, then reinitiate at 50mcg once every five days.

SOURCE / realpeptides.co ↗
04What If My Prolactin Rises to 25 ng/mL (Normal Male Range: 4–15 ng/mL)?+

Prolactin elevation above 20 ng/mL in males can cause gynecomastia (breast tissue development), reduced libido, and erectile dysfunction through suppression of gonadotropin-releasing hormone (GnRH) signalling. If prolactin rises modestly (20–30 ng/mL) without symptoms, reduce CJC-1295 dose by 30–50% and retest in four weeks. Many cases resolve with dose adjustment. If prolactin exceeds 30 ng/mL or symptoms develop, discontinue CJC-1295 and consider cabergoline (a dopamine agonist that lowers prolactin) under medical supervision.

SOURCE / realpeptides.co ↗
05What if I use modified CJC-1295 (no DAC) instead of CJC-1295 with DAC?+

You're using a completely different compound with a completely different pharmacokinetic profile. Modified CJC-1295 without DAC has a half-life under 30 minutes. Identical to native GHRH. And requires multiple daily injections to maintain any GH response. The dosing protocols validated in CJC-1295 pharmacology studies do not apply to modified CJC-1295, and the sustained IGF-1 elevation documented in Phase II trials will not occur. If your research objective is to replicate the results from published CJC-1295 studies, you need the DAC-modified version.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Monitoring and Safety Considerations for CJC-1295 Research

Before starting any CJC-1295 30s age specific protocol, establish baseline biomarkers: serum IGF-1, fasting glucose, HbA1c, and thyroid panel (TSH, free T3, free T4). Growth hormone elevation affects glucose metabolism and thyroid conversion, so tracking these markers every 8–12 weeks prevents undetected metabolic shifts. IGF-1 is the primary efficacy marker. Expect a 40–80ng/mL increase from baseline at effective doses, with peak levels occurring 4–6 weeks into a cycle. If IGF-1 doesn't elevate by at least 20% after four weeks, either the peptide is underdosed, improperly stored, or you're a non-responder. Fasting glucose and HbA1c matter because chronic GH elevation causes insulin resistance through direct antagonism at the insulin receptor. This is why acromegaly patients develop diabetes. Short-term CJC-1295 cycles at physiological doses rarely cause clinically significant insulin resistance, but researchers with pre-existing metabolic dysfunction (prediabetes, NAFLD, metabolic syndrome) should monitor glucose more closely. If fasting glucose rises above 100mg/dL or HbA1c climbs during a cycle, stop the protocol and address insulin sensitivity through diet and exercise before resuming. Thyroid conversion can slow under elevated GH. Specifically, T4-to-T3 conversion in the liver decreases, which can create subclinical hypothyroid symptoms (fatigue, cold sensitivity, brain fog) even if TSH remains normal. This is uncommon at conservative CJC-1295 doses but worth monitoring if symptoms emerge. Retest free T3 mid-cycle if you notice unexpected fatigue despite adequate sleep and recovery. Most researchers don't need thyroid intervention, but those already running low-normal free T3 (<3.0pg/mL) may benefit from temporary T3 supplementation during the cycle. Our team recommends working with peptides sourced from verified suppliers that provide third-party purity testing via HPLC (high-performance liquid chromatography) and mass spectrometry. Real Peptides maintains strict quality control across our catalog, ensuring every batch meets pharmaceutical-grade purity standards before distribution. Peptide degradation during shipping or improper reconstitution is the most common cause of non-response. If you're using a supplier that doesn't refrigerate inventory or provide COA documentation, you're injecting an unknown compound at an unknown concentration. The information in this article is for educational purposes. Dosage, cycling, and monitoring decisions should be made in consultation with a licensed healthcare provider familiar with peptide research protocols. The CJC-1295 30s age specific protocol isn't about maximizing IGF-1 at all costs. It's about leveraging a peptide that still works efficiently at this age while your pituitary retains most of its responsiveness. Waiting until your 50s to learn how GHRH analogs affect your physiology means starting from a much weaker baseline. Running conservative cycles now, with proper monitoring and realistic expectations, builds the knowledge base that matters when the decline accelerates later. If the peptide concerns you, establish baseline IGF-1 before considering it. Knowing where you stand costs nothing and changes the entire risk-benefit calculation.

RESEARCH

CJC-1295 Fasting Break Fast: What Autophagy Researchers Care About

There's a distinction between metabolic fasting (absence of caloric intake) and autophagy-optimized fasting (absence of mTOR activation). For fat loss or ketosis maintenance, CJC-1295 is entirely compatible. It doesn't provide calories, doesn't spike insulin, and actively promotes lipolysis. For autophagy maximization, the question is more nuanced. mTOR is the central regulator of autophagy. When mTOR is active, autophagy is suppressed. mTOR is activated by insulin, amino acids (especially leucine, arginine, and methionine), and growth factors including IGF-1 (insulin-like growth factor 1). CJC-1295 increases endogenous growth hormone, which in turn elevates IGF-1 synthesis in the liver. IGF-1 is a potent mTOR activator. Does this mean CJC-1295 blocks autophagy? Not necessarily. The relationship is dose- and context-dependent. A 2019 study published in Cell Metabolism found that growth hormone administration in fasted mice did not significantly reduce autophagic flux in skeletal muscle or liver tissue despite elevated IGF-1, likely because the absence of amino acids and insulin kept mTOR activation below the threshold required to fully suppress autophagy. For researchers prioritizing autophagy, the conservative approach is to inject CJC-1295 at the end of the fasting window or immediately upon breaking the fast, rather than mid-fast. This preserves the autophagy-induction phase (typically hours 16–24 of a fast) while still capturing the anabolic and lipolytic benefits of elevated GH during the fed window. If fat loss is the primary goal and autophagy is secondary, injection timing is less critical. GH elevation during fasting actively supports the metabolic outcome you're pursuing.

05

Product & matchup locker

Linked catalog and comparison files.

Comparison

CJC-1295 Myths Cost Money Health: Comparison

This table contrasts the most common CJC-1295 myths against the evidence-based reality and the financial cost of operating under the misconception. All suppliers offer equivalent …

Comparison

CJC-1295 (No DAC) vs. CJC-1295 with DAC: A Critical Comparison

Understanding the fundamental differences between CJC-1295 (no DAC) and CJC-1295 with DAC is absolutely crucial for any researcher venturing into CJC-1295 sustained GH therapy. Wh…

Comparison

CJC-1295 Tendon Healing: Protocol Comparison

Dosing Frequency 1–2× weekly 2–3× daily N/A DAC offers compliance advantage for multi-month protocols IGF-1 Elevation Pattern Sustained 1.5–2.5× baseline for 6–8 days Pulsatile pe…

Continue reading

Related articles